Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103864 | 0.83 | PSMB8 (0.48) | PRMT5PSMB8TLR7DPP4DPP8 | |
| SCHEMBL102626 | 0.80 | PRMT5 (0.60) | PRMT5PSMB8DPP4DPP8PDE10A | |
| SCHEMBL30971490 | 0.78 | PRMT5 (0.58) | PRMT5PSMB8DPP4DPP8PDE10A | |
| SCHEMBL102304 | 0.78 | PSMB8 (0.42) | PRMT5PSMB8DPP4DPP8PDE10A | |
| SCHEMBL103972 | 0.77 | MAPT (0.57) | PDE10AMAPTHDAC6SMN1; SMN2NPC1 | |
| SCHEMBL102977 | 0.76 | PSMB8 (0.41) | PRMT5PSMB8DPP4DPP8PDE10A | |
| SCHEMBL21263258 | 0.71 | PRMT5 (0.66) | PRMT5PSMB8DPP4PDE10AMAPT | |
| SCHEMBL5104145 | 0.69 | PRMT5 (1.00) | PRMT5PSMB8DPP4DPP8SMN1; SMN2 | |
| SCHEMBL12585231 | 0.68 | PRMT5 (0.46) | PRMT5PSMB8DPP4DPP8MAPT | |
| SCHEMBL27470340 | 0.67 | PRMT5 (0.45) | PRMT5PSMB8DPP4DPP8PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883826-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-11-11 | — | — | US | disclosed |
| US-8674106-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2426115-A2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | Addex Pharma SA (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-8101637-B2 | Alkynyl derivatives as modulators of metatropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | PRMT5 532/4885PSMB8 4230/4885TLR7 493/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | PRMT5 510/4885PSMB8 4600/4885TLR7 445/4885 |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | PRMT5 532/4885PSMB8 4230/4885TLR7 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.